Tim Williams - Journalist Profile | Connect with top journalists

Beats

Biography

Digital Content Manager at KDKA, CBS Pittsburgh.

Content

Total articles 494

• Available on paid plans

  Mass. governor: Lead pipe replacement funding delay is 'dangerous'

  By Tim Williams

  Mar. 26, 2025

• Available on paid plans

  Pirates Prospect Watch: Five Standouts From the Spring Breakout Game

  By Tim Williams

  Mar. 15, 2025

• Available on paid plans

  Mass. governor: Lead pipe replacement funding delay is 'dangerous'

  By Tim Williams

  Mar. 26, 2025

As seen in

Company Info

CSL

CSL, headquartered in Melbourne, Australia, is a global biotechnology leader with operations in over 30 countries. Founded in 1916 and privatized in 1994, CSL develops and manufactures biotherapeutics, vaccines, and specialty pharmaceuticals aimed at treating rare and serious medical conditions. The company employs more than 32,000 people and reported $14.8 billion in revenue in 2024. CSL operates through four main divisions: CSL Behring, which specializes in plasma-derived therapies; CSL Plasma, which manages plasma collection networks; CSL Seqirus, a major producer of influenza vaccines; and CSL Vifor, focusing on therapies for iron deficiency and kidney disease. The company offers a range of products, including immunoglobulins, seasonal and pandemic vaccines, and iron deficiency treatments. CSL is committed to quality and innovation, maintaining a strong focus on patient needs and compliance with global regulatory standards.